Versant Venture Management, LLC 13F Holdings · Q2 2026
Versant Venture Management, LLC reported 8 securities worth $162.61M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: GLUE (47.34%), IPSC (18.33%), JBIO (13.55%). Among its top 25 positions this quarter: 1 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics, Inc. | $77.0M | 47.34% | 3.2M | Hold |
| 2 | IPSC | Century Therapeutics, Inc. | $29.8M | 18.33% | 12.2M | Hold |
| 3 | JBIO | Jade Biosciences, Inc. | $22.0M | 13.55% | 991,783 | Trimmed |
| 4 | LENZ | Lenz Therapeutics, Inc. | $15.1M | 9.28% | 2.7M | Hold |
| 5 | CTNM | Contineum Therapeutics, Inc. | $8.9M | 5.47% | 542,628 | Hold |
| 6 | CRSP | CRISPR Therapeutics AG | $8.1M | 4.99% | 148,831 | Hold |
| 7 | SKYE | Skye Bioscience, Inc. | $1.4M | 0.86% | 2.0M | Hold |
| 8 | TPST | Tempest Therapeutics, Inc. | $299,447 | 0.18% | 269,772 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR